EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510)

Tadaaki Nishikawa iD, Shigeki Kakunaga iD, Kenji Tamura, Masashi Ando, Toshifumi Ozaki iD, Akira Kawai iD, Takafumi Ueda iD, Mamiko Kawasaki iD, Sawako Tomatsuri iD, Nobuko Okamura, Masahisa Kamikura iD, Akinobu Hamada iD und 5 weitere

Cancer · 15.11.2024 · 130 (22) · 3836-3844

DOI: 10.1002/cncr.35483 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, online erschienen am 30.07.2024. Verfasst von Tadaaki Nishikawa und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Sarcoma, Alveolar Soft Part, Nivolumab, Sarcoma, Clear Cell. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Ono Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clear cell sarcoma (CCS) and alveolar soft part sarcoma (ASPS) are rare, and standard systemic therapy is not established except for sunitinib in ASPS. It is known that CCS and ASPS have a common biological feature of melanoma and Xp11.2/TFE3 translocation renal cell carcinoma, and immune‐checkpoint inhibitors (ICIs) are effective in these tumors. The authors conducted a phase 2 trial to evaluate the efficacy and safety of nivolumab for CCS and ASPS.

Methods

The number of patients expected to be enrolled was 15–25 and was determined based on the Bayesian design. The primary end point was the confirmed objective response rate (ORR) according to the central review and the secondary end points included ORR, progression‐free survival (PFS), overall survival (OS), and safety.

Results

A total of 26 patients (CCS, 12; ASPS, 14) were enrolled. Efficacy and safety were analyzed on 25 and 26 patients, respectively. The minimum number of responses required for a positive conclusion regarding the efficacy was four. However, only one patient (4.0%) with ASPS had a partial response. Complete response, stable disease, progression disease, and not evaluable were 0%, 60%, 32%, and 4.0%, respectively. Adverse events of grade 3 or 4 occurred in 57.7% (15 of 26). The median PFS was 4.9 months (95% confidence interval [CI], 3.7–8.6 months) and the median OS was 15.8 months (95% CI, 8.2–not reached).

Conclusions

The primary end point of the ORR was not met for CCS and ASPS on the central review. Further studies are needed to evaluate ICIs in patients with ASPS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, Alveolar Soft PartNivolumabSarcoma, Clear CellHumansFemaleMaleAdultMiddle AgedAgedYoung AdultProgression-Free SurvivalAntineoplastic Agents, ImmunologicalImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

MITF‐associated tumorOSCAR Trialalveolar soft part sarcomaclear cell sarcomanivolumab

Substanzen

NivolumabAntineoplastic Agents, ImmunologicalImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
  • Department of Orthopedic Surgery, National Hospital Organization Osaka National Hospital, Chuo-ku, Osaka, Japan.
  • Department of Orthopedic Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.
  • Department of Medical Oncology, Shimane University, Izumo, Shimane, Japan.
  • Department of Medical Oncology, Aichi Cancer Center, Chikusa-ku, Nagoya, Aichi, Japan.
  • Department of Orthopedic Surgery, Okayama University, Kita-ku, Okayama, Japan.

ORCID-Profile: Tadaaki Nishikawa, Shigeki Kakunaga, Toshifumi Ozaki, Akira Kawai, Takafumi Ueda, Mamiko Kawasaki, Sawako Tomatsuri, Masahisa Kamikura, Akinobu Hamada, Akihiko Yoshida, Akihiro Hirakawa, Kenichi Nakamura, Kan Yonemori

Förderung

  • Japan Agency for Medical Research and Development
  • Ono Pharmaceutical

Zitieren

APA

Nishikawa, T., Kakunaga, S., Tamura, K., Ando, M., Ozaki, T., Kawai, A., Ueda, T., Kawasaki, M., Tomatsuri, S., Okamura, N., Kamikura, M., Hamada, A., Yoshida, A., Hirakawa, A., Shibata, T., Nakamura, K., & Yonemori, K. (2024). Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510). Cancer, 130(22), 3836-3844. https://doi.org/10.1002/cncr.35483

Vancouver

Nishikawa T, Kakunaga S, Tamura K, Ando M, Ozaki T, Kawai A, et al. Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510). Cancer. 2024;130(22):3836-3844. doi:10.1002/cncr.35483

BibTeX
@article{Nishikawa2024,
  author = {Nishikawa, Tadaaki and Kakunaga, Shigeki and Tamura, Kenji and Ando, Masashi and Ozaki, Toshifumi and Kawai, Akira and Ueda, Takafumi and Kawasaki, Mamiko and Tomatsuri, Sawako and Okamura, Nobuko and Kamikura, Masahisa and Hamada, Akinobu and Yoshida, Akihiko and Hirakawa, Akihiro and Shibata, Taro and Nakamura, Kenichi and Yonemori, Kan},
  title = {Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510)},
  journal = {Cancer},
  year = {2024},
  volume = {130},
  number = {22},
  pages = {3836--3844},
  doi = {10.1002/cncr.35483}
}
Kostenlos starten →